Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC ...( Updated phase 2 data continue to sh...),Health

Updated phase 2 data continue to show encouraging anti-tumor activity in non- small cell lung cancer; Phase 1 data demonstrate tolerability of daily

XL647 administration

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today reported updated data from a phase 2 study of XL647, an inhibitor of EGFR, HER2 and VEGFR kinases, in previously untreated, clinically selected non-small cell lung cancer (NSCLC) patients. The data continue to show encouraging anti-tumor activity for XL647 administered on an intermittent schedule. Additionally, XL647 was generally well tolerated and showed pharmacodynamic target modulation in an ongoing phase 1 study evaluating daily dosing in patients with advanced solid tumors. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held October 22-26, 2007 in San Francisco.

Consistent with data from the phase 2 study reported in September 2007 at the 12th International Association for the Study of Lung Cancer World Conference on Lung Cancer, 68% of the 34 patients evaluable for tumor response had clinical benefit: 10 patients had partial responses (eight confirmed, two not yet confirmed), and 13 patients had stable disease as their best response. All seven patients with activating EGFR mutations experienced tumor shrinkage (six PRs and one SD), and three patients with wild type EGFR achieved partial responses (Abstract #B124). XL647 was generally well tolerated in this patient population.

Additionally, data from a phase 1 dose-escalation study evaluating daily dosing of XL647 were presented (Abstract #B242). As of August 8, 2007,
'/>"/>